| 发明名称 | Dosing regimen for sedation with CNS 7056 (Remimazolam) | ||
| 摘要 | The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg. | ||
| 申请公布号 | US9561236(B2) | 申请公布日期 | 2017.02.07 |
| 申请号 | US201113883935 | 申请日期 | 2011.11.07 |
| 申请人 | PAION UK LTD. | 发明人 | Wilhelm-Ogunbiyi Karin;Borkett Keith;Tilbrook Gary Stuart;Wiltshire Hugh |
| 分类号 | A61K31/5517;A61K31/4468;A61K45/06 | 主分类号 | A61K31/5517 |
| 代理机构 | Nelson Mullins Riley & Scarborough LLP | 代理人 | Nelson Mullins Riley & Scarborough LLP ;Remillard, Esq. Jane E.;Kanik Cynthia L. |
| 主权项 | 1. A method of sedating a subject comprising administering to the subject an initial dose of the besylate salt of 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]-propionic methyl ester (CNS 7056) of formula (I) wherein the initial dose is a fixed dose of between about 2 mg and about 10 mg and is irrespective of the body weight of the subject, in combination with one or more doses of an opioid. | ||
| 地址 | Cambridge GB | ||